We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Comen Medical

Samsung

Develops, manufactures, and markets diagnostic products and solutions for IVD and point-of-care applications read more Featured Products: More products

Download Mobile App





Samsung Biologics and Enzolytics to Jointly Develop and Manufacture Anti-SARS-CoV-2 Monoclonal Antibody Therapies

By HospiMedica International staff writers
Posted on 11 Oct 2021
Print article
Illustration
Illustration

Samsung Biologics (Incheon, Korea), a contract development and manufacturing organization, and Enzolytics Inc. (Plano, TX, USA), a drug development company committed to commercializing multiple proprietary therapeutics to treat debilitating infectious diseases, have entered into a strategic CDMO partnership agreement for the development and manufacturing of anti-HIV and anti-SARS-CoV-2 monoclonal antibody therapies.

Under the terms of the agreement, Samsung Biologics will provide end-to-end CDMO services from cell line development, clinical drug substance, and drug product manufacturing services to support IND filings for anti-HIV and anti-SARS-CoV-2 Monoclonal Antibodies for the treatment of HIV and SARS-CoV-2. In addition, there will be continuing discussions for other monoclonal antibodies being developed by Enzolytics. The Enzolytics protocol offers the opportunity to implement AI analysis and provides a platform for creating multiple fully human monoclonal antibodies targeting conserved immutable sites on the virus and offering a cure for these viruses. A stable cell line will be manufactured with support from Samsung Biologics' R&D Center in San Francisco. Its related clinical trial materials will be manufactured at Samsung Biologics headquarters in Incheon, South Korea.

“Partnering with Enzolytics reinforces the value of our fully integrated, end-to-end business model, which is designed to meet the unique needs and goals of our biotech clients,” said John Rim, CEO of Samsung Biologics. “We look forward to providing comprehensive services and professional support for the manufacturing of this important class of Monoclonal Antibody therapeutics for the treatment of HIV and SARS-CoV-2, helping to accelerate the process of drug development to IND filing and bring these life-saving products to patients.”

“The collaboration with Samsung Biologics is a significant milestone for Enzolytics' Artificial Intelligence enabled Monoclonal Antibody Platform. We chose to partner with Samsung Biologics because of Samsung Biologics' extensive experience and expertise in developing, producing, and manufacturing Monoclonal Antibodies for Infectious Diseases and Oncology,” said Dr. Gaurav Chandra, Chief Operating Officer Research and Development at Enzolytics. “This partnership marks a pivotal milestone for Enzolytics to significantly advance the clinical development of our universal, durable, broadly neutralizing Monoclonal Antibodies and reduce time to the clinic and offer the much-needed treatment for patients.”

Related Links:
Samsung Biologics 
Enzolytics Inc. 


Print article

Channels

Critical Care

view channel
Image: ID NOW (Photo courtesy of Abbott)

Abbott Displays Its Life-Changing POC Tests and Diagnostic Tools at MEDLAB Middle East

At the 2022 edition of MEDLAB Middle East, Abbott (Lake Forest, IL, USA) showcased its portfolio of life-changing diagnostic tools and medical devices for point-of-care testing that help manage patients... Read more

Business

view channel
Illustration

IBM Sells Watson Health Assets to Focus on Platform-Based Hybrid Cloud and AI Strategy

IBM (Armonk, NY, USA) and Francisco Partners (San Francisco, CA, USA) have signed a definitive agreement under which Francisco Partners will acquire healthcare data and analytics assets from IBM that are... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.